The FDA approved Curium’s “radioligand equivalent” to Novartis’ Lutathera, establishing the first generic competitor in the radioligand category. The clearance sets up direct regulatory and commercial rivalry for radiopharmaceutical therapies that rely on targeted radiation delivery. Industry observers expect the approval to intensify pricing and procurement discussions among hospitals and nuclear medicine providers, especially where competing agents can be used under similar imaging and therapy frameworks. With the radioligand class continuing to expand clinically, this approval marks a turning point from brand-only market dynamics toward the introduction of regulated alternatives.